Research programme: diabetes cell therapies - Sernova

Drug Profile

Research programme: diabetes cell therapies - Sernova

Alternative Names: Cell Pouch™ - diabetes cell therapy; Sertolin™ - diabetes cell therapy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JDRF; Sertoli Technologies
  • Developer Sernova Corp
  • Class Cell therapies
  • Mechanism of Action Immunomodulators; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Canada (SC, Implant)
  • 10 Sep 2015 Sernova in-licenses proprietary stem cell derived technologies from the University Health Network (UHN) of Toronto for insulin-dependent diabetes
  • 23 Apr 2015 Sernova receives patent allowance for Cell Pouch™ technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top